<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In Papua New Guinea <z:hpo ids='HP_0000572'>visual loss</z:hpo> is a frequent sequal to <z:e sem="disease" ids="C0010414" disease_type="Disease or Syndrome" abbrv="">Cryptococcus neoformans</z:e> var. gattii <z:hpo ids='HP_0001287'>meningitis</z:hpo> in immunocompetent patients </plain></SENT>
<SENT sid="1" pm="."><plain>We have previously postulated that <z:hpo ids='HP_0000572'>visual loss</z:hpo> may occur as a result of the immunological response to <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> around the optic nerve </plain></SENT>
<SENT sid="2" pm="."><plain>This retrospective study set out to explore the effect of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> on visual outcome </plain></SENT>
<SENT sid="3" pm="."><plain>Sixteen patients received varying doses of <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> (mainly 100-250 mg of <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi> daily for the prevention of febrile reactions to amphotericin) and 10 received anticryptococcal therapy alone </plain></SENT>
<SENT sid="4" pm="."><plain>Visual deterioration occurred less frequently in those treated with <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> (2/16 [12.5%] vs. 7/10 [70%], P = 0.007), <z:hpo ids='HP_0000618'>blindness</z:hpo> was less frequent (1/16 [5.3%] vs. 5/10 [50%], P = 0.018), and in 3 patients vision improved </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="50858">Corticosteroids</z:chebi> may have a role in preventing or halting <z:hpo ids='HP_0000572'>visual loss</z:hpo> in C. neoformans var. gattii <z:hpo ids='HP_0001287'>meningitis</z:hpo> in immunocompetent patients </plain></SENT>
</text></document>